12 completed, 2 withdrawn, 1 active not recruiting, 1 recruiting. 14 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 10, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow bimagrumab: new trials by email Literature Review of bimagrumab trials Research Report on bimagrumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity Bimagrumab, Tirzepatide, Calcium/Vitamin D - Obesity | Phase 2 | Recruiting | Massachusetts General Hospital | 63 | 2025-11-05 | 2026-03-27 |
| A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes Bimagrumab, Tirzepatide, Bimagrumab Placebo - Obesity, Overweight | Phase 2 | Withdrawn | Eli Lilly and Company | 2025-05-23 | 2025-09-24 | |
| A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation - Healthy | Phase 1 | Completed | Eli Lilly and Company | 125 | 2025-03-25 | 2025-10-09 |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight Bimagrumab, Tirzepatide, Bimagrumab Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Eli Lilly and Company | 252 | 2024-10-21 | 2026-05-26 |
| Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese Bimagrumab, Semaglutide, Placebo - Obesity, Obese | Phase 2 | Completed | Eli Lilly and Company | 507 | 2022-11-16 | 2026-07-08 |
| Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes BYM338 10 mg/kg, Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Novartis Pharmaceuticals | 78 | 2017-02-01 | 2021-01-05 |
| An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Bimagrumab, Placebo - Sporadic Inclusion Body Myositis | Phase 3 | Completed | Novartis Pharmaceuticals | 211 | 2015-11-02 | 2018-03-13 |
| A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study bimagrumab, Placebo - Sarcopenia | Phase 2 | Completed | Novartis Pharmaceuticals | 160 | 2015-07-22 | 2020-06-16 |
| Dose Range Finding Study of Bimagrumab in Sarcopenia bimagrumab, placebo - Sarcopenia | Phase 2 | Completed | Novartis Pharmaceuticals | 217 | 2014-12-09 | 2021-01-05 |
| Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery bimagrumab, placebo - Muscle Wasting (Atrophy) After Hip Fracture Surgery | Phase 2 | Completed | Novartis Pharmaceuticals | 251 | 2014-09-16 | 2020-08-19 |
| Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients BYM338, Placebo - Mechanical Ventilation | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2014-04-01 | 2015-01-07 | |
| Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis BYM338 (Bimagrumab) - Sporadic Inclusion Body Myositis (sIBM) | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 10 | 2014-03-11 | 2020-12-30 |
| Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients BYM338/bimagrumab, Placebo - Sporadic Inclusion Body Myositis | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 251 | 2013-09-26 | 2017-08-11 |
| BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia Placebo, BYM338 - Chronic Obstructive Pulmonary Disease (COPD) With Cachexia | Phase 2 | Completed | Novartis Pharmaceuticals | 67 | 2012-09-01 | 2016-05-03 |
| A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults BYM338, Placebo - Skeletal Muscle | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2012-01-01 | 2020-12-17 |
| Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis BYM338, Placebo - Sporadic Inclusion Body Myositis | Phase 2 | Completed | Novartis Pharmaceuticals | 14 | 2011-08-01 | 2020-12-17 |
Muscular Atrophy (6) · Obesity (5) · Myositis, Inclusion Body (4) · Overweight (3) · Cachexia (2) · Diabetes Mellitus, Type 2 (2) · Platelet Glycoprotein IV Deficiency (2) · Sarcopenia (2) · Atrophy (1) · Hip Fractures (1) · Myositis (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Insufficiency (1)
Novartis Pharmaceuticals (11) · Eli Lilly and Company (4) · Massachusetts General Hospital (1)
United States (15) · Australia (6) · Japan (6) · Belgium (5) · France (5) · Switzerland (5) · United Kingdom (5) · Denmark (4) · Czechia (3) · Netherlands (3) · Russia (3) · Spain (3) · Taiwan (3) · Argentina (2) · Germany (2)
PMID 25381300, PMID 30095981, PMID 31397289, PMID 32690797, PMID 33074327, PMID 33439265, PMID 33597289, PMID 36098133, PMID 40230053, PMID 41772149
2015 (2)